Selected research
Market Structure
Global Hyperimmune Serum Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hyperimmune Serum market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hyperimmune Serum is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hyperimmune Serum is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hyperimmune Serum is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hyperimmune Serum is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hyperimmune Serum include ADMA Biologics, Biotest, CBPO, CNBG, CSL Behring, Emergent (Cangene), Grifols, Kamada and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hyperimmune Serum market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hyperimmune Serum and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hyperimmune Serum sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperimmune Serum market size, projected growth trends, production technologies, key applications, and end-use industries.
Hyperimmune Serum Segment by Company
ADMA Biologics
Biotest
CBPO
CNBG
CSL Behring
Emergent (Cangene)
Grifols
Kamada
Kedrion
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
Hyperimmune Serum Segment by Type
Rho(D) Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Hepatitis B Immunoglobulins
Other
Hyperimmune Serum Segment by Application
Government Institutions
Private Sector
Other
Hyperimmune Serum Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Serum market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Serum and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Serum.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hyperimmune Serum market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hyperimmune Serum manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hyperimmune Serum in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hyperimmune Serum in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Rho(D) Immunoglobulins
- Rabies Immunoglobulins
- Tetanus Immunoglobulins
- Hepatitis B Immunoglobulins
- Other
Applications
- Government Institutions
- Private Sector
- Other
Companies covered
- ADMA Biologics
- Biotest
- CBPO
- CNBG
- CSL Behring
- Emergent (Cangene)
- Grifols
- Kamada
- Kedrion
- Hualan Bio
- Shanghai RAAS
- Sichuan Yuanda Shuyang
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hyperimmune Serum Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hyperimmune Serum Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hyperimmune Serum Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hyperimmune Serum Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hyperimmune Serum Market Dynamics
- 2.1 Hyperimmune Serum Industry Trends
- 2.2 Hyperimmune Serum Industry Drivers
- 2.3 Hyperimmune Serum Industry Opportunities and Challenges
- 2.4 Hyperimmune Serum Industry Restraints
3 Hyperimmune Serum Market by Manufacturers
- 3.1 Global Hyperimmune Serum Revenue by Manufacturers (2021-2026)
- 3.2 Global Hyperimmune Serum Sales by Manufacturers (2021-2026)
- 3.3 Global Hyperimmune Serum Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hyperimmune Serum Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hyperimmune Serum Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hyperimmune Serum Manufacturers, Product Type & Application
- 3.7 Global Hyperimmune Serum Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hyperimmune Serum Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hyperimmune Serum Players Market Share by Revenue in 2025
- 3.8.3 2025 Hyperimmune Serum Tier 1, Tier 2, and Tier 3
4 Hyperimmune Serum Market by Type
- 4.1 Hyperimmune Serum Type Introduction
- 4.1.1 Rho(D) Immunoglobulins
- 4.1.2 Rabies Immunoglobulins
- 4.1.3 Tetanus Immunoglobulins
- 4.1.4 Hepatitis B Immunoglobulins
- 4.1.5 Other
- 4.2 Global Hyperimmune Serum Sales by Type
- 4.2.1 Global Hyperimmune Serum Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hyperimmune Serum Sales by Type (2021-2032)
- 4.2.3 Global Hyperimmune Serum Sales Market Share by Type (2021-2032)
- 4.3 Global Hyperimmune Serum Revenue by Type
- 4.3.1 Global Hyperimmune Serum Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hyperimmune Serum Revenue by Type (2021-2032)
- 4.3.3 Global Hyperimmune Serum Revenue Market Share by Type (2021-2032)
5 Hyperimmune Serum Market by Application
- 5.1 Hyperimmune Serum Application Introduction
- 5.1.1 Government Institutions
- 5.1.2 Private Sector
- 5.1.3 Other
- 5.2 Global Hyperimmune Serum Sales by Application
- 5.2.1 Global Hyperimmune Serum Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hyperimmune Serum Sales by Application (2021-2032)
- 5.2.3 Global Hyperimmune Serum Sales Market Share by Application (2021-2032)
- 5.3 Global Hyperimmune Serum Revenue by Application
- 5.3.1 Global Hyperimmune Serum Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hyperimmune Serum Revenue by Application (2021-2032)
- 5.3.3 Global Hyperimmune Serum Revenue Market Share by Application (2021-2032)
6 Global Hyperimmune Serum Sales by Region
- 6.1 Global Hyperimmune Serum Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hyperimmune Serum Sales by Region (2021-2032)
- 6.2.1 Global Hyperimmune Serum Sales by Region (2021-2026)
- 6.2.2 Global Hyperimmune Serum Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hyperimmune Serum Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hyperimmune Serum Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hyperimmune Serum Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hyperimmune Serum Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hyperimmune Serum Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hyperimmune Serum Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hyperimmune Serum Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hyperimmune Serum Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hyperimmune Serum Revenue by Region
- 7.1 Global Hyperimmune Serum Revenue by Region
- 7.1.1 Global Hyperimmune Serum Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hyperimmune Serum Revenue by Region (2021-2026)
- 7.1.3 Global Hyperimmune Serum Revenue by Region (2027-2032)
- 7.1.4 Global Hyperimmune Serum Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hyperimmune Serum Revenue (2021-2032)
- 7.2.2 North America Hyperimmune Serum Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hyperimmune Serum Revenue (2021-2032)
- 7.3.2 Europe Hyperimmune Serum Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hyperimmune Serum Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hyperimmune Serum Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hyperimmune Serum Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hyperimmune Serum Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 ADMA Biologics
- 8.1.1 ADMA Biologics Company Information
- 8.1.2 ADMA Biologics Business Overview
- 8.1.3 ADMA Biologics Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 ADMA Biologics Hyperimmune Serum Product Portfolio
- 8.1.5 ADMA Biologics Recent Developments
- 8.2 Biotest
- 8.2.1 Biotest Company Information
- 8.2.2 Biotest Business Overview
- 8.2.3 Biotest Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Biotest Hyperimmune Serum Product Portfolio
- 8.2.5 Biotest Recent Developments
- 8.3 CBPO
- 8.3.1 CBPO Company Information
- 8.3.2 CBPO Business Overview
- 8.3.3 CBPO Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 CBPO Hyperimmune Serum Product Portfolio
- 8.3.5 CBPO Recent Developments
- 8.4 CNBG
- 8.4.1 CNBG Company Information
- 8.4.2 CNBG Business Overview
- 8.4.3 CNBG Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 CNBG Hyperimmune Serum Product Portfolio
- 8.4.5 CNBG Recent Developments
- 8.5 CSL Behring
- 8.5.1 CSL Behring Company Information
- 8.5.2 CSL Behring Business Overview
- 8.5.3 CSL Behring Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 CSL Behring Hyperimmune Serum Product Portfolio
- 8.5.5 CSL Behring Recent Developments
- 8.6 Emergent (Cangene)
- 8.6.1 Emergent (Cangene) Company Information
- 8.6.2 Emergent (Cangene) Business Overview
- 8.6.3 Emergent (Cangene) Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Emergent (Cangene) Hyperimmune Serum Product Portfolio
- 8.6.5 Emergent (Cangene) Recent Developments
- 8.7 Grifols
- 8.7.1 Grifols Company Information
- 8.7.2 Grifols Business Overview
- 8.7.3 Grifols Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Grifols Hyperimmune Serum Product Portfolio
- 8.7.5 Grifols Recent Developments
- 8.8 Kamada
- 8.8.1 Kamada Company Information
- 8.8.2 Kamada Business Overview
- 8.8.3 Kamada Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Kamada Hyperimmune Serum Product Portfolio
- 8.8.5 Kamada Recent Developments
- 8.9 Kedrion
- 8.9.1 Kedrion Company Information
- 8.9.2 Kedrion Business Overview
- 8.9.3 Kedrion Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Kedrion Hyperimmune Serum Product Portfolio
- 8.9.5 Kedrion Recent Developments
- 8.10 Hualan Bio
- 8.10.1 Hualan Bio Company Information
- 8.10.2 Hualan Bio Business Overview
- 8.10.3 Hualan Bio Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Hualan Bio Hyperimmune Serum Product Portfolio
- 8.10.5 Hualan Bio Recent Developments
- 8.11 Shanghai RAAS
- 8.11.1 Shanghai RAAS Company Information
- 8.11.2 Shanghai RAAS Business Overview
- 8.11.3 Shanghai RAAS Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Shanghai RAAS Hyperimmune Serum Product Portfolio
- 8.11.5 Shanghai RAAS Recent Developments
- 8.12 Sichuan Yuanda Shuyang
- 8.12.1 Sichuan Yuanda Shuyang Company Information
- 8.12.2 Sichuan Yuanda Shuyang Business Overview
- 8.12.3 Sichuan Yuanda Shuyang Hyperimmune Serum Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Sichuan Yuanda Shuyang Hyperimmune Serum Product Portfolio
- 8.12.5 Sichuan Yuanda Shuyang Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hyperimmune Serum Value Chain Analysis
- 9.1.1 Hyperimmune Serum Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hyperimmune Serum Production Mode & Process
- 9.2 Hyperimmune Serum Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hyperimmune Serum Distributors
- 9.2.3 Hyperimmune Serum Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst